Driven. For a Sustainable Life. Samsung Biologics aspires to lead the industry in protecting our planet for the health of future generations. In our mission to enrich human life while creating enduring and sustainable value, we are investing in practices and technologies to mitigate the risks of climate change in the greater areas we impact. As a global CDMO partner, we recognize the greater impact we can have by working together, and essential to our decarbonization is the cooperation and engagement with our suppliers to accelerate the net zero transition across our supply chains. A blossom of hope We are on a journey to help create a healthier adn sustainable future. Our path to changing the world is never ending. It touches everyone and everything. Together we are Driven. For a Sustainable Life. Driven. For Life. Samsung Biologics ESG Report We're committed to sharing oursustainable progress and goals.Learn more about our sustainability initiatives. Find out more Our InvolvementsWe are committed to global carbon neutrality SMI Sustainable Markets Initiative(SMI) A low-carbon transition engagement led by the British royal family,Samsung Biologics participated as a representative of the global CDMO industryto seek a net-zero supply chain plan Find out more on the SMI website The SMI was launched by HRH The Prince of Wales at the World Economic Forum in 2020. It aims to lead the transition to a sustainable future by convening leaders to bring economic value into alignment with social and environmental sustainability. In 2021, the SMI Health Systems Taskforce was formally launched at COP26 in Glasgow including 13 leaders from across the healthcare system with CEOs/equivalents from: AstraZeneca, GSK, Merck, Roche, Samsung Biologics, Sanofi, Novo Nordisk, the World Health Organization, UNICEF, NHS England, the Sustainable Healthcare Coalition, the Karolinska Institute and the University of Pavia. With its shared ambition to accelerate the delivery of net zero, sustainable healthcare to improve individual, societal and planetary health, the SMI Health Systems Taskforce is committed to delivering action in three priority areas through the establishment of Working Groups: Supply Chains (championed by John Rim, CEO Samsung Biologics). The Supply Chains Working Group is focused on accelerating the net zero transition across health systems supply chains. More specifically, the group aims to work with suppliers to decarbonize upstream product supply chains, with a focus on renewable energy, clean heat, green logistics and common supplier standards. Patient Care Pathways (championed by Paul Hudson, CEO Sanofi). The Patient Care Pathways Working Group focuses on identifying opportunities to deliver net zero patient care while improving health and societal outcomes. The group aims to demonstrate how interventions across the care pathway can drive emissions reductions by decarbonizing care settings, preventing and managing disease progression, and delivering lower-CO2 solutions. Digital Healthcare (championed by Belén Garijo, CEO Merck). The Digital Healthcare Working Group focuses on leveraging digital innovation and technology in order to drive the transition to net zero across health systems. The initial focus of the group is on demonstrating how digital solutions can support reducing emissions across clinical trials while improving patient outcomes and the patient experience. Frontier 1.5D The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels.Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, Financial Supervisory Service, to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future. As a business sector representative, Samsung Biologics wi

manufacturing partner to ensure a stable supply of life-saving drugs, especially in light of the current pandemic. ISO22301 is especially meaningful given our critical mission to the biopharma industry to providing patients with a stable supply of life-saving therapies under any circumstances OverviewOperating system Content Tab OverviewOperating system Overview Business Continuity Management System (BCMS, ISO22301) Samsung Biologics’ holistic management process that identifies potential threats to an organization and the impacts to business operations from such threats; and provides a framework for building organizational resilience with the capability of an effective response that safeguards the interests of its key stakeholders, reputation, brand and value-creating activities. Purpose of BCMS Samsung Biologics is operating Business Continuity Management System (BCMS) to protect the assets of our company and clients from risks and to stably deliver key products and services to patients. Leadership for BCMS Operation Samsung Biologics hereby pledges to protect the assets of our company and clients from risk and to stably deliver key products and services to patients to comply with our Business Continuity Management policy. We strive to identify and evaluate the risk of disruption to Samsung Biologics' activities in order to be a global leading company by implementing processes to prevent and mitigate the impact of disruption through continuous improvement. We establish a dedicated organization to routinely manage and continually improve suitability, adequacy, and effectiveness throughout the entire whole business continuity management process. We pledge to be a reliable company for our clients and shareholders by actively participating in BCM activities to stably deliver key products and services. Samsung Biologics President & CEOJohn Rim ISO22301 ISO22301 is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness. Samsung Biologics became the first Korean pharmaceutical company to achieve ISO22301 certificate in 2018, and has continuously expanded the scope of certification for ensuring systemic BCMS management. Operating system BCMS Steering Group Samsung Biologics has three levels of teams in the response structure. The strategic, tactical, and operational teams in a response structure undertake different activities as follows: Crisis Management Committee Emergency Response - Evacuation- Initial Site response- First aid- Restoration- And others Business Support - Supply Chain- HR- Finance- Quality- And others Manufacturing - Drug Substance- Drug Product- Research- Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strateg

CEO IR NEWSLETTER Driven. For Life.SAMSUNG BIOLOGICS 2025.04Dear valued investors and shareholders, This is John Rim from Samsung Biologics. We extend our sincere appreciation for your unwavering trust and support, which remain the cornerstone of our company's growth and success.Key HighlightsQ1 Financial Performance. Robust earnings driven by Plant 4 and FX tailwinds - Consolidated: Rev. 1,298B, OP. 487B (OPM: 37.5%) - Biologics : Rev. 1,000B, OP. 430B (OPM: 43.0%) - Bioepis : Rev. 401B, OP. 128B (OPM: 31.9%) . Annual sales growth guidance maintained at +20-25% * Consolidated basisCDMO. Signed a record-breaking $1.4B CMO contract *EU-based big pharma . CDO business expansion with global pharma demand . Won CDMO Leadership Awards for 12 consecutive years . Continued order intake: $17.8B cum. contract volume - Total 102 CMO Products and 137 CDO ProductsBusiness Expansion. Commenced operations at ADC facility . Completed Plant 5 construction (Operational since Apr. '25) . Investment in C2N Diagnostics through Life Science Fund . Opened a sales office in Tokyo, JapanBiosimilar· SB17 (bStelara) : US launch (Feb. '25) · SB12 (bSoliris) : US partnership with Teva (Jan. '25) *Marketing & Commercialization . Product launched in Apr. '25 · SB16 (bProlia, bXgeva) : EC & US FDA Approval (Feb. '25)Today, Samsung Biologics released our financial results for the first quarter of 2025. Amid a persistently challenging business environment shaped by geopolitical tensions, macroeconomic uncertainty, and policy volatility, we achieved strong results, driven by resilient operational execution and a disciplined commitment to operational excellence. On a consolidated basis, revenue reached KRW 1.3 trillion, primarily driven by the steady operational stabilization of Plant 4, increased sales of biosimilar products, and FX tailwinds. In light of potential currency fluctuations and the broader uncertainty surrounding the global macroeconomic landscape, we continue to expect that our full-year performance will be in line with the guidance communicated earlier this year. As always, should external developments warrant a refined perspective on our outlook, we will engage with the market in a timely and transparent manner. Amid ongoing signals of potential tariff actions on pharmaceuticals by the U.S. administration, we are closely monitoring prospective policy shifts and associated risks. We acknowledge the possible ramifications for our clients and ultimately, for patients, and will be working closely with our clients to develop countermeasures that can be implemented swiftly and effectively. We remain committed to delivering reliable and sustainable results grounded in our resilient business model and robust operational capabilities.Demonstration of Global CDMO Leadership through Strong Order Intake and Proven Client Satisfaction Global Competitiveness Underpinned by Enduring Client Trust and Operational Excellence Building on our commitment to exceptional quality and client-centric execution, we continue to solidify our market leadership by achieving significant business milestones. In January, we entered into a landmark CMO agreement valued at approximately USD 1.4 billion (KRW 2 trillion) with a leading European pharmaceutical company - marking the largest single order in our history, accounting for nearly 40% of our total annual order volume for 2024. Since then, we have been actively engaged in discussions with both existing and prospective clients for additional orders, further reinforcing our growth trajectory. Our CDO business also continues to advance steadily, supported by ongoing advancement of our platform technologies and service capabilities. While sustaining stable collaborations with existing partners, we are broadening our client portfolio, thereby strengthening our position as a fully integrated CDMO through enhanced synergy between our CMO and CDO operations. We are honored to have once ag

manufacturing approvals *340 approvals in totalBusiness Expansion• Completion of ADC facility construction• P5 at Biocampus II to be operational in Apr. '25• Investment in PFS Mother-line (CGMP ready by Oct. 27) *Foundational set-up for future global expansion• Continued investments via Life Science Fund *Flagship Pioneening, BrickBio, Latus Bio, Generate BiomedicinesBiosimilar• SB17 (bStelara): EU launch & US FDA approval * Launched in EU, including Germany, Spain, France and the Netherlands• SB15 (bEylea):EC & US FDA approval• SB12 (bSoliris) :US FDA approval• SB16 (bProlia):Positive CHMP opinion *EMA's Committee for Medicinal Products for Human UseToday, Samsung Biologics announced our financial results for the fourth quarter and full year of 2024.Fiscal year 2024 was marked by a global economic slowdown and heightened geopolitical tensions. Despite these challenging environments, Samsung Biologics achieved robust performance through customer-centric services and operational excellence.Most notably, we achieved a transformative milestone by becoming the first company within the Korean biopharmaceutical industry to surpass KRW 4.5 trillion in annual revenue. This unprecedented financial performance, setting a new company record with an impressive 23% year-over-year growth, underscores our cutting-edge expertise, distinctive competencies, and the unwavering confidence our clients place in us, thereby reaffirming our market leadership and global competitiveness.As we embark on 2025, we are proud to announce that we have achieved a record-breaking order worth KRW 2 trillion on January 14th, the highest contract volume in our company's history. This remarkable accomplishment not only reinforces our market leadership but also fuels our continued growth momentum, and we remain dedicated to excellence in customer satisfaction by supporting the reliable supply of critical medicines to patients around the world without any delay.Looking ahead to 2025, we foresee an even more robust financial trajectory, propelled by the successful ramp-up of our Plant 4 coupled with the continued full utilization of Plants 1 through 3. Building on this momentum, we have established an annual revenue growth target of 20~25%, positioning us to surpass KRW 5 trillion mark in consolidated revenue within just 14 years of our founding. We take pride in sharing this positive outlook with our esteemed investors, reaffirming our unwavering commitment to driving sustainable growth, broadening our global presence, and optimizing shareholder value.Sustained and Stable Growth of CDMO Business Record-Breaking Contract Wins, Driven by Exceptional Capabilities and Client TrustWe reached an unprecedented milestone in 2024, surpassing KRW 5 trillion in annual contract wins, collaborating with a number of global pharmaceutical giants across the US, Asia, and Europe. This extraordinary achievement was highlighted by a succession of groundbreaking contracts that underscore our prominence in the global pharmaceutical landscape: a KRW 1.45 trillion agreement with a US-based pharmaceutical company in July, followed by a KRW 1.7 trillion contract with an Asian pharmaceutical company in October. Also, entering 2025, we secured our largest contract to date - a KRW 2 trillion agreement with a Europe-based pharmaceutical company in January.Our strategic focus on expanding partnerships with global Top 20 pharmaceutical companies has yielded impressive results. In 2024, we successfully forged partnerships with three additional global top 20 big pharmaceutical companies, bringing our total collaborations within this group to 17. This accomplishment stands as a testament to our unrivaled industry standing and the solid trust our clients place in our capabilities and quality.Our CDO division has also made significant strides, successfully launching four innovative platforms in 2024 - S-TensifyTM, S-AfuCHOTM, S-OptiChargeTM, and S-HiConTM - as well as a service package tailored to mee

manufacturing processes. This support facility, situated strategically at the center of the campus, is poised to play a pivotal role in optimizing production processes and enhancing efficiency, ensuring swift responsiveness to customer needs. Our endeavor to expand our business capability with ADC is also progressing smoothly. Consisting of a 500L conjugation reactor and one purification line, our ADC conjugation facility is scheduled to start operations by the end of the year. Also, through the Samsung Life Science Fund, we have been investing in biotechs around the world with advanced ADC technologies to secure a competitive edge in the ADC field and proactively address market demands. Through these strategic efforts, we aim to build a comprehensive ADC toolbox, thus broadening the scope of services that we can offer to our clients.Growth of CDO with New Platforms Introduction of SelecTailor™, S-Tensify™, and DEVELOPICK™ Ver. 3.0In order to meet the evolving CDO demands of our growing client base, we are committed to expanding new platforms while continuously improving our existing ones. As part of this effort, we introduced our rebranded SelecTailor™ service package and launched our innovative S-Tensify™ platform. Additionally, we unveiled the revamped version 3.0 of our established DEVELOPICK™ platform. S-Tensify™ platform stands out as a high-density cell culture solution, providing nutrient-rich media and effectively eliminating impurities prior to the main cultivation phase. This helps achieve high-concentration cell culture by increasing the inoculation cell density at the stage just before the final cell culture (N-1) by an average of 30 times, leading productivity to be substantially boosted during the final cell culture stage. Meanwhile, SelecTailor™ is designed to support customized biopharmaceutical development, aligning closely with specific customer requirements. This rebranded Customized CMC Solution is expected to not only provide bespoke services based on customers' diversified characteristics and propose development strategies to support successful new drug development, but also enhance our competitive edge in the market. Building upon these strengths and comprehensive service offerings, we are expanding our global reach and remain dedicated to delivering even better results to our existing and potential clients in the future.Continued Investment into New Modalities Investment into Flagship Pioneering Fund VIII to Support New Drug DevelopmentIn July, Samsung Biologics decided to invest USD 52.23 million (KRW 72 billion) in Flagship Pioneering Fund VIII through the Samsung Life Science Fund II, established jointly with Samsung C&T, Samsung Bioepis, and Samsung Venture Investment. Flagship Pioneering is a premier U.S. venture capital firm which manages about USD 14 billion (approx. KRW 19 trillion) in assets and has founded over 100 companies. This Flagship Pioneering Fund VIII, valued at USD 2.6 billion, focuses on platform technologies for new drug development leveraging artificial intelligence (Al). With priority access to and continued investments in innovative biotechs, Samsung Biologics aims to ultimately support and promote significant advancements in drug development.Digital Transformation Client-centered business process optimization through Automation and DigitizationSamsung Biologics is enhancing its CDMO competitiveness by implementing Digital Transformation across all operational areas, from technology transfer to manufacturing processes, aiming to optimize our customer-centric business processes. More specifically, we are trying to maximize efficiency through various activities including implementation of electronic manufacturing batch records (EMBR), use of integrated digital management systems, and adoption of Generative Al. Additionally, we have classified our operations into five categories, each tasked with specific initiatives to drive